BD Q3 revenue $5.5B (+10.4%); adjusted EPS $3.68; raises FY guidance to $14.30-$14.45

BECTON DICKINSON & CO

2025-Q3 EPS reported $4.10 vs consensus $3.96 ▲ beat (+3.5%)

Revenue of $5.5B, up 10.4% as reported and 3.0% organic; GAAP EPS $2.00, adjusted EPS $3.68.
GAAP gross margin up 160 bps; adjusted gross margin up 50 bps; GAAP operating income up 46.6%.
Company raises full-year adjusted diluted EPS guidance to $14.30-$14.45 (up $0.18 at midpoint); reaffirms organic revenue growth guidance.
Expects to complete remaining $250M of $1B share buyback commitment by end of fiscal 2025.
In July, announced definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters Corporation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.